Paul Tudor Jones’s IDXX Holdings & Trades

First Buy
Q2 2013
Duration Held
50 Quarters
Largest Add
Q1 2025
+36,086 Shares
Current Position
6,614 Shares
$4.23 M Value

Paul Tudor Jones's IDXX Position Overview

Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 6,614 shares of IDEXX Laboratories, Inc. (IDXX) worth $4.23 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.

Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in IDXX, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 36,086 shares. Largest reduction occurred in Q2 2025, reducing 20,125 shares.

Analysis based on 13F filings available since 2013 Q2

Paul Tudor Jones's IDEXX Laboratories (IDXX) Holding Value Over Time

Track share changes against reported price movement

Quarterly IDEXX Laboratories (IDXX) Trades by Paul Tudor Jones

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2013 +6,002 Add 0.00% 6,000 $44.83
Q3 2013 -6,000 Sold Out 6,000 $0.00
Q4 2013 +4,814 New Buy 4,814 $53.18
Q1 2014 -4,814 Sold Out 4,814 $0.00
Q2 2014 +3,200 New Buy 3,200 $66.88
Q3 2014 +17,882 Add 558.81% 21,082 $58.91
Q4 2014 -16,682 Reduce 79.13% 4,400 $74.09
Q1 2015 -4,400 Sold Out 4,400 $0.00
Q2 2015 +10,730 New Buy 10,730 $64.12
Q3 2015 -19 Reduce 0.18% 10,711 $74.22
Q4 2015 -10,711 Sold Out 10,711 $0.00
Q2 2016 +5,712 New Buy 5,712 $92.79
Q3 2016 -1,113 Reduce 19.49% 4,599 $112.63
Q4 2016 -4,599 Sold Out 4,599 $0.00
Q4 2017 +4,524 New Buy 4,524 $156.28
Q1 2018 -3,117 Reduce 68.90% 1,407 $191.19
Q2 2018 +2,405 Add 170.93% 3,812 $218.00
Q3 2018 -780 Reduce 20.46% 3,032 $249.67
Q4 2018 -3,032 Sold Out 3,032 $0.00
Q1 2020 +4,791 New Buy 4,791 $242.33
Q2 2020 -1,328 Reduce 27.72% 3,463 $330.06
Q3 2020 +3,103 Add 89.60% 6,566 $393.09
Q4 2020 +4,138 Add 63.02% 10,704 $499.91
Q1 2021 -4,155 Reduce 38.82% 6,549 $489.23
Q2 2021 -6,549 Sold Out 6,549 $0.00
Q3 2021 +5,911 New Buy 5,911 $621.89
Q4 2021 -5,911 Sold Out 5,911 $0.00
Q2 2022 +11,619 New Buy 11,619 $350.72
Q3 2022 -7,387 Reduce 63.58% 4,232 $325.85
Q4 2022 +7,750 Add 183.13% 11,982 $0.41
Q1 2023 -11,982 Sold Out 11,982 $0.00
Q2 2023 +13,393 New Buy 13,393 $502.23
Q3 2023 -10,991 Reduce 82.07% 2,402 $437.27
Q4 2023 -2,402 Sold Out 2,402 $0.00
Q2 2024 +1,280 New Buy 1,280 $487.20
Q3 2024 -1,280 Sold Out 1,280 $0.00
Q4 2024 +1,966 New Buy 1,966 $413.44
Q1 2025 +36,086 Add 1835.50% 38,052 $419.95
Q2 2025 -20,125 Reduce 52.89% 17,927 $536.34
Q3 2025 -11,313 Reduce 63.11% 6,614 $638.89

Paul Tudor Jones's IDEXX Laboratories Investment FAQs

Paul Tudor Jones first purchased IDEXX Laboratories, Inc. (IDXX) in Q2 2013, acquiring 6,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones has held IDEXX Laboratories, Inc. (IDXX) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones's largest addition to IDEXX Laboratories, Inc. (IDXX) was in Q1 2025, adding 38,052 shares worth $15.98 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 6,614 shares of IDEXX Laboratories, Inc. (IDXX), valued at approximately $4.23 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, IDEXX Laboratories, Inc. (IDXX) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones's peak holding in IDEXX Laboratories, Inc. (IDXX) was 38,052 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.